Background
Gordon Cranston Wishart was born in Edinburgh, Scotland, on 3 September 1960.
- Photos
- Works
- Photos
- Works
Gordon Wishart
Edit Profile
Professor Gordon C Wishart Bachelor of Medicine Bachelor of Surgery Master of Arts Doctor of Medicine Fellowship of the Royal College of Surgeons Fellowship of the Royal College of Surgeons Fellowship of the Royal College of Surgeons is a consultant breast & endocrine surgeon at Addenbrooke"s Hospital, Cambridge.
Education
He studied at Edinburgh University Medical School, where he obtained his Bachelor of Medicine Bachelor of Surgery (Bachelor of Medicine, Bachelor of Surgery) degree in July 1983.
Career
He is distinguished for his pioneering work in the treatment of breast cancer, where he has introduced innovative, and sometimes controversial, techniques which have subsequently seen wide acceptance and adoption. He subsequently obtained his Doctor of Medicine from Edinburgh University in June 1992 with a thesis entitled Aspects of multidrug resistance in breast cancer. Gordon Wishart currently holds the following posts: Medical Director, BreastHealth United Kingdom Visiting Professor of Cancer Surgery, Anglia Ruskin University Associate Lecturer, Faculty of Clinical Medicine, University of Cambridge He also acts as a referee for the British Journal of Surgery, the European Journal of Surgical Oncology, and Nuclear Medicine Communications.
Achievements
-
In 1990, Gordon Wishart identified that P-glycoprotein, a transport-membrane export pump involved in multidrug resistance, was present in breast cancer. In 1998, he introduced early patient discharge, with wound drains still in situ, following breast cancer surgery. Although controversial at the time this technique has since been widely adopted. Wishart pioneered minimally invasive parathyroid surgery as a daycase procedure in the United Kingdom, together with the use of intra-operative parathyroid hormone (PTH) measurement for parathyroid surgery. In 2007, Wishart piloted gold seed insertion following breast conserving surgery for breast cancer to facilitate targeted radiotherapy. In 2009, he pioneered pre-operative axillary lymph node staging in breast cancer treatment.
